SEC Form 3 FORM 3

## UNITED STATES SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

## OMB APPROVAL

3235-OMB Number: 0104

## **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF** SECURITIES

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and A<br><u>Muni Nea</u>   | 2. Date of<br>Requiring<br>(Month/Da<br>05/19/20                    | Statement<br>ay/Year)  | 3. Issuer Name and Ticker or Trading Symbol <u>Comera Life Sciences Holdings, Inc.</u> [ CMRA ] |   |  |                                    |  |  |  |  |
|--|---|--|---|---|--|------------------------------------|--|--|--|--|
| (Last)   | (First) (Middle)  |  |   | 4. Relationship of Reporting<br>Issuer<br>(Check all applicable)                  | 10% Owner<br>Other (specify<br>below)  |                                    | 5. If Amendment, Date of Original<br>Filed (Month/Day/Year)  |  |  |  |
| (Street)<br>WOBURN<br>(City)   | REET, SUITE 4650         MA       01801         (State)       (Zip) | _  |   | Director<br>X Officer (give<br>title below)<br>See Rema                           |  |                                    | 6. Individual or Joint/Group Filing<br>(Check Applicable Line)<br>X Form filed by One Reporting<br>Person<br>Form filed by More than One<br>Reporting Person |  |  |  |
| Table I - Non-Derivative Securities Beneficially Owned   |   |  |   |   |  |                                    |  |  |  |  |
| 1. Title of Security (Instr. 4)  |   |  |   | 2. Amount of Securities<br>Beneficially Owned (Instr.<br>4)                       | Form: D<br>(D) or In                   |                                    |  | 4. Nature of Indirect Beneficial<br>Ownership (Instr. 5) |  |  |
| Common Stock   |   |  |   | 0   | D                                      | D                                  |  |  |  |  |
| Table II - Derivative Securities Beneficially Owned           (e.g., puts, calls, warrants, options, convertible securities) |   |  |   |   |  |                                    |  |  |  |  |
| E (1)  |   | 2. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |   | 3. Title and Amount of Securities<br>Underlying Derivative Security<br>(Instr. 4) |  | 4.<br>Conver<br>or Exer<br>Price o | sion<br>cise   | 5.<br>Ownership<br>Form:<br>Direct (D)                   | 6. Nature of<br>Indirect Beneficial<br>Ownership (Instr.<br>5) |  |
|  |   | Date<br>Exercisable  | Expiration<br>Date  | Title   | Amount<br>or<br>Number<br>of<br>Shares |                                    |  | or Indirect<br>(I) (Instr. 5)                            | 5)   |  |
| Stock Option   | n (Right to Buy) <sup>(1)</sup>                                     | 09/16/2022   | 09/16/2031  | Common Stock  | 208,199                                | 0.7                                | 7  | D  |  |  |
| Explanation of Despanses   |   |  |   |   |  |                                    |  |  |  |  |

Explanation of Responses:

1. The option vests in four annual increments beginning on September 16, 2022.

**Remarks:** 

Executive Vice President and Chief Operating Officer

/s/ Neal Muni

05/20/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.